• Markets
  • icon
  • Companies
IMU · ASX

Imugene Ltd (ASX:IMU)

AU$0.069

 -0.002 (-2.817%)
ASX:Live
24/05/2024 12:39:44 PM
HALO Small HALO Ords HALO Consensus Value GROWTH AUS EMA 125 Breakdown +2
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

IMU Overview

IMU Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Very Strong

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About IMU

Telephone

Address

Description

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.

IMU Price Chart

Key Stats

Market Cap

AU$490.43M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.04 - 0.15

Trade Value (12mth)

AU$671,622.00

1 week

-1.39%

1 month

-14.46%

YTD

-35.45%

1 year

-38.26%

All time high

0.625

Key Fundamentals

EPS 3 yr Growth

130.800%

EBITDA Margin

N/A

Operating Cashflow

-$30m

Free Cash Flow Return

-18.10%

ROIC

-23.00%

Interest Coverage

-1,788.10

Quick Ratio

27.20

Other Data

Shares on Issue (Fully Dilluted)

6882m

HALO Sector

Next Company Report Date

30-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

5.20

IMU Announcements

Latest Announcements

Date Announcements

06 May 24

Application for quotation of securities - IMU

×

Application for quotation of securities - IMU

30 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

23 April 24

Change of Director's Interest Notice - PH

×

Change of Director's Interest Notice - PH

19 April 24

Notification regarding unquoted securities - IMU

×

Notification regarding unquoted securities - IMU

17 April 24

Imugene & Kincell Bio Strategic Partnership Investor Webinar

×

Imugene & Kincell Bio Strategic Partnership Investor Webinar

16 April 24

Imugene and Kincell Bio Announce Strategic Partnership

×

Imugene and Kincell Bio Announce Strategic Partnership

15 April 24

Bile Tract Cancer Study Opens after MAST High Dose Clearance

×

Bile Tract Cancer Study Opens after MAST High Dose Clearance

15 April 24

Notification regarding unquoted securities - IMU

×

Notification regarding unquoted securities - IMU

15 April 24

Notification of cessation of securities - IMU

×

Notification of cessation of securities - IMU

08 April 24

VAXINIA and HER-Vaxx featured at the AACR Annual Meeting

×

VAXINIA and HER-Vaxx featured at the AACR Annual Meeting

04 April 24

Oncolytic Virotherapy CF33 Patent Granted in China

×

Oncolytic Virotherapy CF33 Patent Granted in China

03 April 24

Imugene to present at 2024 Cholangiocarcinoma Conference

×

Imugene to present at 2024 Cholangiocarcinoma Conference

02 April 24

Application for quotation of securities - IMU

×

Application for quotation of securities - IMU

02 April 24

Cleansing Notice

×

Cleansing Notice

11 March 24

Phase 1 onCARlytics Trial Advances to Combination Arm

×

Phase 1 onCARlytics Trial Advances to Combination Arm

29 February 24

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

15 February 24

Phase 1 onCARlytics Trial Doses First Intravenous Patient

×

Phase 1 onCARlytics Trial Doses First Intravenous Patient

02 February 24

Notice of change of interests of substantial holder - PH

×

Notice of change of interests of substantial holder - PH

01 February 24

Application for quotation of securities - IMU

×

Application for quotation of securities - IMU

01 February 24

Application for quotation of securities - IMU

×

Application for quotation of securities - IMU

01 February 24

Cleansing Notice

×

Cleansing Notice

01 February 24

Change of Director's Interest Notice - PH

×

Change of Director's Interest Notice - PH

31 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

19 January 24

VAXINIA Phase 1 trial doses patients in higher dose cohorts

×

VAXINIA Phase 1 trial doses patients in higher dose cohorts

19 January 24

Imugene CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI

×

Imugene CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI

IMU Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -53.8 -67.5 10.4 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.01 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -5.0 -108.8 -4.2 Lock Lock Lock
     Yield % Lock Lock Lock Lock -0.8 -3.0 0.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.02 0.03 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.02 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -8.5 197.8 37.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 4,664 5,637 6,276 Lock Lock Lock
Basic m Lock Lock Lock Lock 4,664 5,637 6,276 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 24 48 49 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -2,278.8 -22.7 8.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -24 -48 -49 Lock Lock Lock
     Growth % Lock Lock Lock Lock -60.2 -103.6 -1.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -26 -51 -51 Lock Lock Lock
     Growth % Lock Lock Lock Lock -72.5 -97.4 -1.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -26 -50 -50 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -7 -13 -12 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -18 -38 -38 Lock Lock Lock
     Growth % Lock Lock Lock Lock -75.6 -105.2 -0.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -13 -31 -30 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 5 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -5 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 18 101 83 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -13 -31 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.9 -133.1 100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 29 100 153 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 72 148 197 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -29 -99 -153 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 7 9 7 Lock Lock Lock
Equity $m Lock Lock Lock Lock 65 139 190 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 65 139 190 Lock Lock Lock
     Growth % Lock Lock Lock Lock 9.0 113.5 36.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -25.7 -25.7 -19.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -28.4 -27.3 -20.0 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -41.0 -49.5 -31.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -29.5 -37.1 -23.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -21.0 -30.0 -18.1 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -4,718.1 -3,554.2 -1,788.1 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.2 2.1 3.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -44.9 -71.5 -80.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 8.1 15.3 27.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 8.1 15.3 27.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 81.2 87.8 92.5 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -294.6 -413.1 -489.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -25.7 -25.7 -19.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -28.4 -27.3 -20.0 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -28.4 -27.3 -20.0 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 164.9 399.8 567.6 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -164.9 -399.8 -567.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

5.20%

Value ($M)

27

Prior Change

-0.10%

7 Day Change

-0.10%

1 Month Change

-0.10%

3 Month Change

-0.40%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IMU Shortsell

Frequently Asked Questions

The current share price of Imugene Ltd (IMU:ASX) is AU$0.069.
The 52-week high share price for Imugene Ltd (IMU:ASX) is AU$0.15.
The 52-week low share price for Imugene Ltd (IMU:ASX)? is AU$0.04.
Imugene Ltd (IMU:ASX) does not pay a dividend.
Imugene Ltd (IMU:ASX) does not pay a dividend.
Imugene Ltd (IMU:ASX) has a franking level of 0.0%.
Imugene Ltd (IMU:ASX) is classified in the Healthcare.
The current P/E ratio for Imugene Ltd (IMU:ASX) is .